Mode
Text Size
Log in / Sign up

Higher third trimester estradiol levels associated with maternal hypothyroxinemia and lower FT4

Higher third trimester estradiol levels associated with maternal hypothyroxinemia and lower FT4
Photo by Logan Voss / Unsplash
Key Takeaway
Note that higher estradiol levels are associated with maternal hypothyroxinemia in this exploratory cohort study.

This study utilized a cohort of 200 women at 28 gestational weeks or later, including 100 women with isolated maternal hypothyroxinemia (IMH) and 100 euthyroid women. The researchers also employed Wistar rats and human astrocytes to investigate the biological mechanisms behind the observed associations.

In the human cohort, higher estradiol (E2) levels were associated with IMH, with an odds ratio of 2.93 per doubling. Additionally, higher E2 was associated with lower FT4, specifically a decrease of 1.74 pmol/L per doubling. The adjusted TSH-FT4 association did not reach statistical significance.

Experimental models provided further data. In the rat model, E2 replacement during late gestation was associated with lower serum FT4, lower pituitary T4, and higher pituitary Dio2 and Oatp1c1, without a statistically significant increase in TSH. In human astrocytes, E2 increased DIO2/OATP1C1 expression and the supernatant T3/T4 ratio, while the addition of ICI 182,780 attenuated these effects.

Safety and tolerability data were not reported. A key limitation is that pituitary thyroid hormone metabolism was not directly assessed in the clinical cohort. The proposed model of pituitary adaptation remains exploratory and should not be viewed as a demonstrated human mechanism.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
IntroductionIsolated maternal hypothyroxinemia (IMH), defined by low free thyroxine (FT4) with thyroid-stimulating hormone (TSH) within the reference range, is a clinically relevant thyroid phenotype in late pregnancy, when estradiol (E2) rises sharply. We tested whether third-trimester E2 is associated with IMH and whether complementary animal and cell data are compatible with a proposed model of pituitary adaptation.MethodsIn 200 women at ≥28 gestational weeks (IMH, n = 100; euthyroid, n = 100), multivariable regression assessed associations of log2(E2) with IMH and FT4 after adjustment for gestational age and maternal age. Complementary experimental studies used gestational-stage Wistar rats, ovariectomized Wistar rats with 17β-E2 replacement, and Human Astrocytes treated with T4 ± E2 ± ICI 182,780.ResultsHigher E2 was associated with IMH (OR 2.93 per doubling) and lower FT4 (−1.74 pmol/L per doubling), whereas the adjusted TSH–FT4 association was not statistically significant. In rats, late gestation and E2 replacement were associated with lower serum FT4, no statistically significant increase in TSH, lower pituitary T4, and higher pituitary Dio2 and Oatp1c1; in the OVX+E2 model, the pituitary T3/T4 ratio was also higher. In Human Astrocytes, E2 increased DIO2/OATP1C1 expression and the supernatant T3/T4 ratio, and ICI attenuated these effects, indicating estradiol responsiveness in a glial-like human cell system.DiscussionTogether, these findings are compatible with altered local thyroid hormone handling under high-E2 conditions, but pituitary thyroid hormone metabolism was not directly assessed in the clinical cohort. The proposed model of pituitary adaptation should therefore be regarded as exploratory and hypothesis-generating rather than as a demonstrated human mechanism.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.